By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

Unlike image recognition or NLP, clinical trial data possesses a unique and complex mathematical geometry. According to Dr. Juraji, this means generic AI models are insufficient. Solving trial failures requires specialized AI built to navigate this specific, difficult data landscape.

Instead of the high-risk approach of replacing a trial's control arm with digital twins, Unlearn.ai adds counterfactual data to every participant. This method increases a trial's statistical power, allowing for smaller control arms or a higher chance of success, while satisfying regulatory constraints for pivotal trials.

The FDA is abandoning rigid, fixed-length clinical trials for a "continuous" model. Using AI and Bayesian statistics, regulators can monitor data in real-time and approve a drug the moment efficacy is proven, rather than waiting for an arbitrary end date, accelerating access for patients.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

It's impossible to generate human data at the scale of in silico experiments. The key is to create highly accurate simulations of human physiology (digital twins) and then validate their predictions with limited, strategic human data. If the model proves reliable, it could drastically accelerate R&D.

Unlearn.ai strategically avoids diseases where a single biomarker determines progression. Instead, they focus on complex, systematic diseases where many variables each have a small impact on the outcome. These are the areas where sophisticated, multi-variable modeling provides the most significant advantage over standard statistical adjustment.

The FDA approved Artera AI’s prostate cancer diagnostic without understanding *why* it works. This precedent suggests that massive retrospective validation on patient data can substitute for model interpretability, changing the strategic focus for medical AI companies.

Unlearn.ai found that scaling digital twins from CNS to oncology isn't about parameter changes. Radically different data structures—like oncology's hierarchy of rare diseases and complex treatment histories—demand entirely new modeling approaches, unlike the more siloed data found in CNS trials.